Iovance Biotherapeutics Initiates Biologics License Application (BLA) Submission for Lifileucel in Advanced Melanoma

Iovance Biotherapeutics, Inc., has initiated a rolling BLA submission to the US FDA for lifileucel, a tumor infiltrating lymphocyte therapy, in patients with advanced melanoma.